U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H12I3NO4
Molecular Weight 650.9735
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIOTHYRONINE

SMILES

N[C@@H](CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1)C(O)=O

InChI

InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H12I3NO4
Molecular Weight 650.9735
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68014284

Liothyronine (CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. The mechanisms by which thyroid hormones exert their physiologic action are not well understood. These hormones enhance oxygen consumption by most tissues of the body, increase the basal metabolic rate and the metabolism of carbohydrates, lipids, and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system. Thyroid hormone drugs are indicated: as the replacement or supplemental therapy in patients with hypothyroidism of any etiology; as pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters; as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

-4.3079041E11
Primary
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

-4.3079041E11
Diagnostic
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

-4.3079041E11
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
346 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
342 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
404 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4370 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4740 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4926 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
12929 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13938 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.04 h
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Disc. AE: Anxiety, Palpitations...
AEs leading to
discontinuation/dose reduction:
Anxiety (severe)
Palpitations
Agitation
Shortness of breath
Irritability
Tachycardia
Tremor
Sources: Page: p.2
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting
Abdominal pain
Headache (severe)
Confusion
Disorientation
Diplopia
Sources: Page: p.2
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
DLT: Anxiety, Tachycardia...
Dose limiting toxicities:
Anxiety (50%)
Tachycardia (50%)
Loose stools (100%)
Sources: Page: p.3
37.5 ug 2 times / day multiple, oral
MTD
Dose: 37.5 ug, 2 times / day
Route: oral
Route: multiple
Dose: 37.5 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 4
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 4
Sources: Page: p.3
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Irritability Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Palpitations Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Shortness of breath Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Tachycardia Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Tremor Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Anxiety severe
Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Abdominal pain Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Confusion Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Diplopia Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Disorientation Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Nausea Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Vomiting Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Headache severe
Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Loose stools 100%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
Anxiety 50%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
Tachycardia 50%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects.
1998 Nov
Arachidonic acid and PGE2 regulation of hepatic lipogenic gene expression.
1999 Jun
Interaction of amiodarone and triiodothyronine on the expression of beta-adrenoceptors in brown adipose tissue of rat.
1999 Mar
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells.
2000 Feb
Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor.
2000 Sep 22
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome.
2001
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs.
2001 Apr
The pituitary-thyroid axis in healthy men living under subarctic climatological conditions.
2001 Apr
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary.
2001 Apr
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air.
2001 Apr
Nuclear cytoplasmic shuttling by thyroid hormone receptors. multiple protein interactions are required for nuclear retention.
2001 Apr 6
[Diabetes mellitus caused by pancreatitis in a bull].
2001 Feb
Differential in vitro suppressive effects of steroids on leukocyte phagocytosis in two teleosts, tilapia and common carp.
2001 Feb
Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators.
2001 Feb
Effect of hypothyroidism on pathways for iodothyronine and tryptophan uptake into rat adipocytes.
2001 Feb
Regulation of mucin gene expression in human tracheobronchial epithelial cells by thyroid hormone.
2001 Feb 1
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism.
2001 Feb 15
Thyroid hormone and the cardiovascular system.
2001 Feb 15
What is the optimal treatment for hypothyroidism?
2001 Feb 5
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis.
2001 Jan
[Diagnosis of hyperthyroidism].
2001 Jan
Endogenous depression, thyroid function and acupuncture.
2001 Jan
Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
2001 Jan
Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle.
2001 Jan
Subclinical thyrotoxicosis.
2001 Jan
Structure and expression of the transthyretin gene in the choroid plexus: a model for the study of the mechanism of evolution.
2001 Jan 1
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo.
2001 Jun 8
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis.
2001 Mar
Characterization of hepatic low-K(m) outer-ring deiodination in red drum (Sciaenops ocellatus).
2001 Mar
Perioperative considerations in a hypothyroid infant with hepatic haemangioma.
2001 Mar
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism.
2001 Mar
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study.
2001 Mar
Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion.
2001 Mar
Homogeneous enzyme immunoassay for triiodothyronine in serum.
2001 Mar
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression.
2001 Mar
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression.
2001 Mar
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase.
2001 Mar 6
Slower skeletal muscle phenotypes are critical for constitutive expression of Hsp70 in overloaded rat plantaris muscle.
2006 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
The relative affinity of the rat synaptosomes for various T3 analogs was measured by incubating [3H]T3 with increasing amounts of T3, D-T3, T4, TRIAC and rT3, The results were expressed as the molar ratio of the concentrations of T3 or analog needed to decreaseby 50% the binding of [3H]T3.
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:28:11 UTC 2022
Edited
by admin
on Fri Dec 16 17:28:11 UTC 2022
Record UNII
06LU7C9H1V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIOTHYRONINE
HSDB   INN   MI   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
LIOTHYRONINE [MI]
Common Name English
LEVOTHYROXINE SODIUM RELATED COMPOUND LIOTHYRONINE [USP IMPURITY]
Common Name English
CYRONINE
Brand Name English
T3
Common Name English
NSC-80203
Code English
LIOTHYRONINE [USP IMPURITY]
Common Name English
3,5,3'-TRIIODOTHYRONINE, L-
Common Name English
LEVOTHYROXINE SODIUM IMPURITY A [EP IMPURITY]
Common Name English
Liothyronine [WHO-DD]
Common Name English
LIOTHYRONINE [VANDF]
Common Name English
O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-L-TYROSINE
Systematic Name English
3,3',5-TRIIODO-L-THYRONINE
Systematic Name English
L-TYROSINE, O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-
Systematic Name English
3,5,3'-TRIIODOTHYRONINE
Systematic Name English
RATHYRONINE, (S)-
Common Name English
ALANINE, 3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)-, L-
Systematic Name English
T-3
Common Name English
TRIIODOTHYRONINE
Systematic Name English
THYRONINE, 3,3',5-TRIIODO-, L-
Systematic Name English
(2S)-2-AMINO-3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)PROPANOIC ACID
Systematic Name English
liothyronine [INN]
Common Name English
LIOTHYRONINE [HSDB]
Common Name English
LIOTHYRONINE [USP-RS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 862.1715
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 83124-8
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 26879-7
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 83125-5
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
FDA ORPHAN DRUG 539116
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
NCI_THESAURUS C1553
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
WHO-VATC QH03AA03
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
NDF-RT N0000006165
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
CFR 21 CFR 862.1710
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
CFR 21 CFR 520.1284
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 3053-6
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 14930-2
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
WHO-ATC H03AA03
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 3055-1
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
NDF-RT N0000175946
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
NCI_THESAURUS C886
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LIVERTOX 1000
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 70152-4
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
NDF-RT N0000006165
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 35231-0
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
LOINC 57899-7
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
Code System Code Type Description
DAILYMED
06LU7C9H1V
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
RS_ITEM_NUM
1368008
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
CAS
57164-27-9
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
SUPERSEDED
DRUG CENTRAL
1585
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
EVMPD
SUB08527MIG
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
EPA CompTox
DTXSID8023216
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
ECHA (EC/EINECS)
229-999-3
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
RXCUI
10814
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY RxNorm
NSC
80203
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
DRUG BANK
DB00279
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
MERCK INDEX
M6835
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY Merck Index
HSDB
3110
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
NCI_THESAURUS
C907
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
INN
653
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
FDA UNII
06LU7C9H1V
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
CHEBI
18258
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
LACTMED
Liothyronine
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
CAS
6893-02-3
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
WIKIPEDIA
LIOTHYRONINE
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
ChEMBL
CHEMBL1544
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
IUPHAR
2634
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
MESH
D014284
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
CHEBI
533015
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
CAS
7013-53-8
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
SUPERSEDED
PUBCHEM
5920
Created by admin on Fri Dec 16 17:28:11 UTC 2022 , Edited by admin on Fri Dec 16 17:28:11 UTC 2022
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
TRANSPORTER -> SUBSTRATE
LABELED -> NON-LABELED
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
MAJOR
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
The relative response factor is 1.00
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY